The price of bitcoin fell below $90,000 and other cryptocurrencies saw large drops Tuesday morning, erasing some of the gains digital assets have made since President Trump took office on a pro-crypto ...
Hosted on MSN15d
'Will Take All Year:' Terry Haines on House GOP Plansaccording to data—and see the rest of the 50 highest-rated cities Ukrainian government sells T-shirts with viral Zelensky quote from disastrous Trump meeting Inflammation on Your Plate ...
Spring is just around the corner, but this year's flu season is still clinging on and causing misery for millions of people ...
Moderna recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded their patent ...
In a couple of regulatory filings with the SEC, it was revealed that Moderna’s CEO Stephane Bancel and director Paul Sagan acquired common stock worth $6 million. On Monday, Bancel acquired ...
Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, a person close to the matter told Fierce Pharma. The layoffs are ...
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological disorder. The phase 3 study is evaluating the candidate, dubbed mRNA-1403 ...
It wasn't all positive for Pfizer and BioNTech on the patent front this week, though. In Germany, the Düsseldorf Regional Court ruled for Moderna in a case that also dates back to 2022. The court ...
(Bloomberg) -- Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for a canceled manufacturing contract. The Cambridge, Massachusetts-based ...
Pharma giant Moderna (MRNA) is set to release its Q4 2024 results on February 14. MRNA stock has lost about 64% over the past year, due to fading vaccine demand and pipeline uncertainty.
Moderna posted a Q4 EPS loss of $(2.91), missing estimates, while revenue fell to $966M from $2.81B but beat the $942.8M consensus Moderna’s norovirus vaccine trial is on FDA hold due to a ...
(Reuters) -Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a rare neurological side effect was reported. The trial of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback